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ABSTRACT UK cystic fibrosis (CF) guidelines recommend eradication of methicillin-resistant
Staphylococcus aureus (MRSA) when cultured from respiratory samples. As there is no clear consensus as
to which eradication regimen is most effective, we determined the efficacy of eradication regimens used in
our CF centre and long-term clinical outcome.
All new MRSA positive sputum cultures (n=37) that occurred between 2000 and 2014 were reviewed.
Eradication regimen characteristics and clinical, microbiological and long-term outcome data were
collected.
Rifampicin plus fusidic acid was the most frequently used regimen (24 (65%) out of 37 patients), with an
overall success rate of 79% (19 out of 24 patients). Eradication failure was more likely in patients with an
additional MRSA-positive peripheral screening swab (p=0.03) and was associated with worse survival (p=0.04).
Our results demonstrate the feasibility and clinical benefits of MRSA eradication. As peripheral
colonisation was associated with lower eradication success, strategies combining systemic and topical
treatments should be considered to optimise outcomes in CF patients.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically significant pathogen in cystic fibrosis
(CF) pulmonary infection. Large cohort studies indicate that chronic respiratory infection with MRSA is
associated with a faster decline in lung function amongst children [1–4] and worse survival in the adult
population [5]. Therefore, current guidelines recommend eradication of MRSA when first isolated in
respiratory samples from CF patients [6, 7].
The UK CF Trust guidelines recommend that a combination of rifampicin and fusidic acid should be
used, with or without inhaled vancomycin, for MRSA airways eradication [6]. However, there is little
evidence to support this recommendation. In fact, the optimal eradication regimen to treat CF MRSA
respiratory infection is currently disputed, with a number of ongoing clinical trials investigating chronic
MRSA eradication strategies [8]. Recent studies have reported small case series, describing a range of
eradication strategies [9, 10]. The duration of eradication regimens described also varies from a few days to
several months [11–13], using either a single agent or a combination of oral and/or intravenous antibiotics
[14, 15]. Inhaled vancomycin was used by some groups but without definitive or conclusive results [16].
Furthermore, the characteristics of the CF populations included were diverse, with some studies
investigating acute MRSA infections only and others incorporating chronically infected patients into their
analyses [13]. A recent Cochrane review found that there is insufficient data to recommend a specific
MRSA eradication regimen, and that prospective studies are warranted [17].
In order to optimise and standardise our current practice, we undertook a retrospective study to determine
the efficacy of the different eradication regimens used in our centre over the past 15 years. Between 2000
and 2014, the Northern Ireland Regional Adult CF Centre (Belfast, UK) patient cohort has steadily
increased, from approximately 150–294 patients. During this time, it was part of our policy to eradicate
new MRSA as soon as it was detected in a respiratory sample culture, without awaiting a second
confirmatory sample. However, no official consensus eradication regimen was established, including
selection of antibiotics and treatment duration. These decisions were made on an individual basis
according to patient medical history (e.g. allergies and liver disease), antimicrobial susceptibility testing
results and clinician preference. As recommended by CF and non-CF specific guidelines [18–20], 2% nasal
mupirocin ointment and 4% chlorhexidine body wash for 5 days were routinely prescribed, in addition to
systemic antibiotics. Inhaled vancomycin was not used in our centre as part of an eradication regimen.
Materials and methods
Study design
Using the clinical microbiology database and the CF registry, we identified patients attending the Northern
Ireland Regional Adult CF Centre who acquired a new MRSA respiratory infection between January 1,
2000 and December 31, 2014. The medical charts of these patients were reviewed to collect relevant
clinical, microbiology and long-term outcome data. This case series study was registered as an audit in the
Belfast Health and Social Care Trust.
Definitions
A new MRSA episode was defined as at least one positive respiratory sample culture (sputum or
oropharyngeal swab) from a person whose previous respiratory cultures (during the previous 12 months)
were negative for MRSA. MRSA was considered successfully eradicated if all respiratory samples, during
the 6-month period following eradication treatment, were MRSA culture negative. A minimum of two
cultures, collected after the end of systemic antibiotic treatment, were required to fulfil the eradication
criteria. Patients who had at least two MRSA-positive sputum cultures over a 6-month period prior to the
first eradication attempt were defined as chronically infected with MRSA.
Statistical analyses
We conducted a descriptive analysis of the antibiotic regimens used and the population treated, based on
data collected at the start of eradication treatment. Continuous variables are expressed as a mean±SD, whilst
categorical variables were expressed using proportions or percentages. Bivariate analyses were conducted
using the Chi-squared or Fisher`s exact test where appropriate. Continuous variables were compared using
a t-test or Mann–Whitney test for non-parametric data. Long-term outcomes were described using
Kaplan–Meier survival curves and differences assessed using the log-rank test. A p-value ⩽0.05 was
considered statistically significant in all analyses.
Results
Description of MRSA episodes
During the study period 38 new MRSA episodes were identified, with a median (range) of 2.5 (0–6) cases·year−1.
Two patients had two distinct episodes that occurred >3–5 years after their first eradication trial.
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One patient spontaneously cleared MRSA infection without any specific eradication treatment. This case
was excluded from subsequent analysis, leaving 37 eligible episodes. 36 (97%) out of 37 MRSA episodes
were acute with the remaining case considered a chronic infection (duration of 33 weeks). For this latter
case, poor attendance at clinic appointments precluded earlier initiation of eradication treatment.
Description of eradication regimens used
Eradication regimens were defined by both the antibiotics chosen and the duration of treatment. According
to these criteria, nine different eradication regimens were used during the study period. As shown in table 1,
42-day treatment with rifampicin and fusidic acid was the most frequent regimen prescribed (20 (54%) out
of 37 patients). This dual therapy was given in four additional cases for a shorter course of 3 weeks.
Monotherapy with doxycycline was used on six occasions, whilst the combination of minocycline with
fusidic acid was prescribed a total of three times. The four remaining regimens were used once.
The overall success rate of the eradication regimens prescribed was 73% (27 out of 37 patients). The
combination of rifampicin with fusidic acid (3- and 6-week courses) was most effective with successful
eradication achieved in 19 (79%) out of 24 identified cases (table 2). Monotherapy with doxycycline was
effective for MRSA eradication in four (66%) out of six cases (table 2). The infrequent use of the remaining
regimens precludes determination of their efficacy. Due to gastrointestinal intolerance, two patients treated
with rifampicin and fusidic acid had their eradication regimen modified while under treatment.
Impact of eradication regimens
To determine the effect of treatment duration on eradication, we compared the success rate of all the
regimens given for ⩽3 weeks (short regimens: n=8) with those given for >3 weeks (long regimen: n=29)
(table 2). There was no statistically significant difference in efficacy (p=0.40, Fisher’s exact test).
We also evaluated whether combination therapy with two antibiotics was more effective than monotherapy.
Amongst eradication failures, four (40%) out of 10 were associated with single agent treatments.
Furthermore, less than one-fifth of the successful eradications (five (18.5%) out of 27) were achieved using
monotherapy. However, these differences were not statistically significant (p=0.22, Fisher’s exact test).
Patient characteristics and long-term outcomes
To identify clinical characteristics that might impact on eradication outcome, we grouped patients as either
eradication success (n=27) or eradication failure (n=10) and compared a range of parameters (table 3).
There was no statistically significant difference between groups with regard to sex and age distribution,
forced expiratory volume in 1 s (FEV1) values, prevalence of pancreatic insufficiency and CF-related
diabetes, Pseudomonas aeruginosa infection status and duration of MRSA infection prior to initiation of
eradication. Although the genotype profile was statistically similar between both groups (p=0.5,
Chi-squared test), there was a higher proportion of F508del-homozygous patients amongst the MRSA
eradication failure group (six (60%) out of 10) compared to the MRSA eradication success group (10
(37%) out of 27). Furthermore, eradication failure was more likely in patients who had at least one positive
peripheral screening swab (nasal and/or skin) (p=0.03, Fisher’s exact test).
Chronic infection with MRSA is associated with a poorer prognosis [1, 5]. Therefore, we compared
long-term clinical outcomes in the two groups (eradication success versus failure). Difference in FEV1
(measured 1 year after initiation of eradication) was not different between both groups. Using Kaplan–Meier
TABLE 1 Use and duration of treatment
Treatment Regimen Total
7 days 14 days 21 days 28 days 42 days
Rifampicin and fusidic acid 4 20 24
Doxycycline 3 3 6
Minocycline and fusidic acid 3 3
Rifampicin and TMP 1 1
Clindamycin 1 1
Teicoplanin 1 1
TMP-SMX 1 1
Total 1 3 4 1 28 37
Data are presented as n. TMP: trimethoprim; TMP-SMX: trimethoprim-sulfamethoxazole.
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survival curves and log-rank statistical analyses (figure 1), no significant difference was detected in the time
elapsed between eradication and the next pulmonary exacerbation requiring intravenous antibiotics.
However, the survival rate was significantly worse amongst the MRSA eradication failure group (four deaths)
compared to those with a successful eradication (two deaths) (p=0.04).
Discussion
Over the study period (2000–2014), the incidence of MRSA infection in our CF population remained low,
with an average of 2.5 new respiratory infections per year. In this study, we reviewed 37 new MRSA
episodes in which an eradication regimen was prescribed and this represents, to our knowledge, the largest
case series investigating eradication of acute MRSA infection. In accordance with current UK guidelines
[6], rifampicin combined with fusidic acid was the preferred regimen in our CF centre, with a success rate
of 79%, which is comparable with the results of previous studies where efficacy of eradication treatments
was approximately 80% [10, 12, 14].
Treatment burden and side-effects are major concerns in the CF population. The combination of
rifampicin and fusidic acid for MRSA airways eradication is frequently associated with gastrointestinal
side-effects [13]. Several week courses with these drugs also necessitate close liver function monitoring and
therapy may not be well tolerated, leading to discontinuation. Two patients treated with rifampicin and
fusidic acid experienced gastrointestinal symptoms that led to a modification of their eradication regimen.
No significant changes in hepatic enzymes were noted. Taking into account the high incidence of
side-effects related to these drugs and the fact that there is no specific duration of treatment recommended
in the current guidelines [6], we compared the efficacy of shorter regimens with those lasting >3 weeks
(table 2). Although strong conclusions are limited by the small number of patients who received a short
TABLE 2 Success rate of individual eradication regimens
Treatment Regimen Overall success rate+
⩽3 weeks# >3 weeks¶
Rifampicin and fusidic acid 4/4 (100) 15/20 (75) 19/24 (79)
Doxycycline 2/3 (66) 2/3 (66) 4/6 (66)
Minocycline and fusidic acid NA 2/3 (66) 2/3 (66)
Rifampicin and TMP NA 1/1 (100) 1/1 (100)
Clindamycin NA 0/1 (0) 0/1 (0)
Teicoplanin 1/1 (100) NA 1/1 (100)
TMP-SMX NA 0/1 (0) 0/1 (0)
Data are presented as n/N (%). TMP: trimethoprim; TMP-SMX: trimethoprim-sulfamethoxazole; NA: not
applicable. #: n=8; ¶: n=29; +: n=37.
TABLE 3 Patient characteristics
Success Failure p-value+
Subjects 27 10
Male/female 17/10 5/5 0.71
Age years 30.9±17.2 28.4±9.5 0.67
Genotype 0.50
F508del homozygous 10 (37) 6 (60)
F508del heterozygous 15 (55.6) 4 (40)
Other 2 (7.4) 0
Pancreatic insufficiency 21 (77.8) 9 (90) 0.65
CF-related diabetes 6 (22.2) 3 (30) 0.68
FEV1 % predicted 66.9±24.1 61.5±18.2 0.57
Pseudomonas aeruginosa# 22 (81.5) 8 (80) 0.92
Duration of infection weeks¶ 3.7±6.6 2.6±3.1 0.60
MRSA carrier nasal/skin swabs 4 (14.8) 6 (60) 0.03
Data are presented as n, mean±SD or n (%). CF: cystic fibrosis; FEV1: forced expiratory volume in 1 s;
MRSA: methicillin-resistant Staphylococcus aureus. #: chronic colonisation; ¶: interval between first positive
culture and start of eradication; +: Chi-squared (Fisher’s exact test where appropriate) or t-test.
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eradication course (n=8), the similar efficacy rates observed between both groups are reassuring (short
course 88% versus long courses 69%). Furthermore, these results are in accordance with a previous study
[14], which also reported that protocols using longer courses of rifampicin and fusidic acid were no more
effective than shorter ones. While awaiting clinical trials that would clarify this question, all these findings
taken together suggest that rifampicin and fusidic acid could be prescribed for 3 weeks to maximise
compliance and minimise side-effects with no compromise on efficacy.
Our study also demonstrated that successful eradication was less likely in patients who had at least one
peripheral screening swab positive for MRSA. This novel finding concurs with the previous hypothesis of
VANDERHELST et al. [21], who postulated that patients with negative nasal screening might be more
susceptible to spontaneous eradication of MRSA without treatment. In our study, all patients were offered
the same nasal/skin decolonisation protocol. Since retrospective evaluation of treatment adherence is
inaccurate, efficacy of topical treatment was not assessed. Nevertheless, as suggested by studies performed
in the non-CF population [22], topical decolonisation is expected to enhance eradication of MRSA
carriage and reduce the likelihood of reinfection. Therefore, a holistic approach combining systemic and
topical treatments with environmental advice (e.g. regular washing of bed linen and towels, avoidance of
toothbrush sharing, etc.) should be employed to optimise MRSA clearance. Additionally, MRSA screening
of household members, with subsequent decolonisation if positive, should also be considered.
Despite both groups of people with CF included in our study having similar clinical characteristics at the
initiation of eradication treatment, the subgroup of patients who were not successfully eradicated had a
worse survival rate than those who underwent successful eradication. This finding supports the results
from a large cohort study [5] and underlines the clinical importance of pro-active management of new
MRSA infection in order to optimise clinical prognosis for CF patients. We also observed that there was a
higher proportion of F508del-homozygous patients in the eradication failure subgroup. This may bias the
results of our work due to the poorer prognosis conferred by this genotype. However, both groups were
otherwise similar, including FEV1 values and, when studying an adult cohort, lung function data may be
more predictive of patient survival than genotype alone [23].
In this study, seven different eradication regimens were observed (table 1). Such heterogeneity of practice
is partly explained by the fact that most of the study period, defined from 2000 to 2014, occurred before
the publication of the first UK guidelines in May 2009, which suggested a specific protocol for MRSA
eradication. Furthermore, clinical guidelines are recommendations and not mandatory lines of practice.
Treatment decisions are made by the clinician on an individual basis according to the medical history of
the patient (e.g. allergies and intolerances) and the antimicrobial susceptibility profile of the bacterial
isolate. This inevitably leads to treatment disparity. Consequently, as previously discussed, the variety of
regimens observed in this study (antibiotics and treatment duration) prevented the elaboration of strong
conclusions with regards to the superiority of a specific eradication protocol.
At the Northern Ireland Regional CF Centre, normal practice is to attempt eradication of MRSA as soon as
one respiratory sample for MRSA is reported. Although a second respiratory sample is routinely collected at
initiation of eradication, the result does not impact on clinical management. In fact, the eradication protocol
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FIGURE 1 Long-term clinical outcomes. a) Time until next exacerbation after methicillin-resistant
Staphylococcus aureus (MRSA) eradication and b) survival after MRSA respiratory infection.
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is continued even if MRSA is not cultured from the second respiratory sample. Amongst our patients, nine
(24%) had only one positive respiratory culture documented. However, two of these patients also had a
concurrent positive peripheral screening swab (nasal, throat or perineal), resulting in seven patients with
only one positive sample. Therefore, our practice results in the treatment of people who may have
spontaneously cleared MRSA infection without therapy. As a result, our observed eradication success rate
may be overestimated. It was previously reported that between one-third and up to half of CF patients
positive for MRSA in a single respiratory sample will spontaneously clear the bacterium without specific
treatment [1, 24]. Furthermore, MRSA isolates were not available for molecular typing, which prevents
determination of whether eradication failure was associated with a single strain. Similarly, it was not possible
to determine if patients with multiple positive samples were persistently infected with the same strain.
Conclusion
Due to its deleterious impact on morbidity and mortality in people with CF, it is widely recognised that
MRSA warrants careful surveillance and pro-active management to prevent establishment of chronic
respiratory infection. This important study showed that patients with positive peripheral screening for
MRSA were less likely to clear their respiratory tract infection. This finding underlines the necessity to
prescribe and promote adherence to topical treatment and environmental decolonisation measures in
addition to systemic antibiotics in order to reduce reinfection. This study also emphasises the feasibility of
MRSA eradication in new onset infections and highlights the detrimental impact on survival if eradication
is not achieved. Results of ongoing and future clinical trials are awaited in order to define the optimal
treatment regimen and duration for eradication of newly acquired MRSA infection in CF.
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